Lifeward Ltd. (LFWD) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Lifeward Ltd. is a medical device company focused on physical rehabilitation and recovery, primarily through its ReWalk exoskeletons for spinal cord injury and AlterG Anti-Gravity systems. The company operates as a single reporting segment with principal markets in the United States and Europe. As of November 12, 2025, the company had 17,732,137 ordinary shares outstanding.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $6.20 million | $6.13 million | $16.95 million | $18.12 million |
| Gross Profit | $2.71 million | $2.22 million | $7.34 million | $6.37 million |
| Gross Margin | 43.7% | 36.2% | 43.3% | 35.2% |
| Operating Loss | $(3.14) million | $(3.17) million | $(14.56) million | $(14.12) million |
| Net Loss | $(3.17) million | $(3.08) million | $(14.57) million | $(13.66) million |
| Cash & Equivalents | $1.96 million (as of Sept 30, 2025) | |||
| Operating Cash Flow (YTD) | $(13.27) million used |
Material Changes vs. Prior Period
- Revenue: Q3 revenue increased slightly (1.1%) year-over-year, driven by record Medicare beneficiary placements. However, YTD revenue decreased 6.4% due to lower average selling prices, a shift to lower-margin segments, and reduced service revenues from AlterG.
- Profitability: Gross margins improved significantly (from 36.2% to 43.7% in Q3) due to the closure of the Fremont manufacturing facility in late 2024 and the transition of production to contract manufacturers.
- Expenses:
- R&D: Decreased 27.8% in Q3 and 31.1% YTD due to the completion of development programs for ReWalk 7 and AlterG NEO.
- Sales & Marketing: Decreased 23.8% in Q3 and 20.5% YTD, reflecting reduced consultant fees and promotional spending.
- G&A: Increased significantly in Q3 ($1.7M increase) and YTD ($2.5M increase). This is largely due to the absence of a $2.0M earnout release benefit recorded in Q3 2024, plus $0.6M in bad debt expense and restructuring costs in the current period.
- Impairment: The company recorded a non-cash goodwill impairment charge of $2.78 million in the first half of 2025 due to a decline in market capitalization below the carrying value of its reporting unit.
Outlook, Risks, and Contingencies
- Going Concern: Management has concluded there is substantial doubt regarding the company's ability to continue as a going concern for the next 12 months. Cash on hand ($2.0M) is estimated to fund operations only into the first quarter of 2026.
- Financing:
- On November 14, 2025 (subsequent to period end), the company secured a $3.0 million loan from Oramed Ltd. at 15% interest, secured by a lien on cash and accounts receivable.
- The company's At-the-Market (ATM) offering program expired on November 12, 2025, limiting immediate equity raise capabilities until a new shelf registration is effective.
- Nasdaq Compliance: The company received a deficiency letter from Nasdaq on August 5, 2025, for failing to maintain a $1.00 minimum bid price. It has until February 2, 2026, to regain compliance or face delisting.
- Reimbursement: The company achieved a legal victory in June 2025 where an Administrative Law Judge ruled ReWalk is a "reasonable and necessary" medical device for Medicare coverage. It also received CE Mark approval for the ReWalk 7 in Europe.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the new $3.0M Oramed loan against the stated burn rate and the timeline to Q1 2026.
- Delisting Risk: Monitor the stock price to ensure it meets the $1.00 minimum bid requirement by February 2026 to avoid Nasdaq delisting.
- ATM Status: Confirm the status of the new Form S-3 registration statement to determine when equity fundraising can resume.
- Medicare Revenue: Assess the sustainability of the "record" Medicare placements and the impact of the new fee schedule on future margins.
- Debt Covenants: Review the specific covenants and default triggers in the Oramed Secured Promissory Note, particularly regarding the lien on cash.